PMID- 37321847
OWN - NLM
STAT- MEDLINE
DCOM- 20231229
LR  - 20240106
IS  - 1741-6612 (Electronic)
IS  - 1440-6381 (Linking)
VI  - 42
IP  - 4
DP  - 2023 Dec
TI  - Examining the use of cannabidiol and delta-9-tetrahydrocannabinol-based medicine 
      among individuals diagnosed with dementia living within residential aged care 
      facilities: Results of a double-blind randomised crossover trial.
PG  - 698-709
LID - 10.1111/ajag.13224 [doi]
AB  - OBJECTIVE: Dementia affects individuals older than 65 years. Currently, 
      residential aged care facilities (RACF) use psychotropic medications to manage 
      behavioural and neuropsychiatric symptoms of dementia (BPSD), which are 
      recommended for short-term use and have substantial side effects, including 
      increased mortality. Cannabinoid-based medicines (CBM) have some benefits that 
      inhibit BPSD and cause minimal adverse effects (AEs), yet limited research has 
      been considered with this population. The study aimed to determine a tolerable 
      CBM dose (3:2 delta-9-tetrahydrocannabinol:cannabidiol), and assessed its effect 
      on BPSD, quality of life (QoL) and perceived pain. METHODS: An 18-week 
      randomised, double-blinded, crossover trial was conducted. Four surveys, 
      collected on seven occasions, were used to measure changes in BPSD, QoL and pain. 
      Qualitative data helped to understand attitudes towards CBM. General linear mixed 
      models were used in the analysis, and the qualitative data were synthesised. 
      RESULTS: Twenty-one participants (77% female participants, mean age 85) took part 
      in the trial. No significant differences were seen between the placebo and CBM 
      for behaviour, QOL or pain, except a decrease in agitation at the end of 
      treatment in favour of CBM. The qualitative findings suggested improved 
      relaxation and sleep among some individuals. Post hoc estimates on the data 
      collected suggested that 50 cases would draw stronger conclusions on the 
      Neuropsychiatric Inventory. CONCLUSIONS: The study design was robust, rigorous 
      and informed by RACF. The medication appeared safe, with minimal AEs experienced 
      with CBM. Further studies incorporating larger samples when considering CBM would 
      allow researchers to investigate the sensitivity of detecting BPSD changes within 
      the complexity of the disease and concomitant with medications.
CI  - (c) 2023 The Authors. Australasian Journal on Ageing published by John Wiley & Sons 
      Australia, Ltd on behalf of AJA Inc'.
FAU - Timler, Amanda
AU  - Timler A
AUID- ORCID: 0000-0003-2619-5937
AD  - Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, 
      USA.
FAU - Bulsara, Caroline
AU  - Bulsara C
AD  - Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, 
      USA.
FAU - Bulsara, Max
AU  - Bulsara M
AD  - Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, 
      USA.
FAU - Vickery, Alistair
AU  - Vickery A
AD  - Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, 
      USA.
AD  - Emerald Clinics, Fremantle, WA, USA.
FAU - Jacques, Angela
AU  - Jacques A
AD  - Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, 
      USA.
FAU - Codde, Jim
AU  - Codde J
AD  - Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, 
      USA.
LA  - eng
GR  - MGC Pharmaceuticals/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230615
PL  - Australia
TA  - Australas J Ageing
JT  - Australasian journal on ageing
JID - 9808874
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 7J8897W37S (Dronabinol)
RN  - 0 (Cannabinoids)
SB  - IM
MH  - Aged
MH  - Humans
MH  - Female
MH  - Aged, 80 and over
MH  - Male
MH  - *Cannabidiol/adverse effects
MH  - Dronabinol/adverse effects
MH  - *Dementia/diagnosis/drug therapy/epidemiology
MH  - Quality of Life
MH  - Cross-Over Studies
MH  - Pain/chemically induced/drug therapy
MH  - *Cannabinoids/adverse effects
OTO - NOTNLM
OT  - cannabinoid
OT  - crossover trial
OT  - dementia
OT  - pain, quality of life
EDAT- 2023/06/16 01:08
MHDA- 2023/12/29 06:43
CRDT- 2023/06/15 21:37
PHST- 2023/04/28 00:00 [revised]
PHST- 2023/02/08 00:00 [received]
PHST- 2023/05/18 00:00 [accepted]
PHST- 2023/12/29 06:43 [medline]
PHST- 2023/06/16 01:08 [pubmed]
PHST- 2023/06/15 21:37 [entrez]
AID - 10.1111/ajag.13224 [doi]
PST - ppublish
SO  - Australas J Ageing. 2023 Dec;42(4):698-709. doi: 10.1111/ajag.13224. Epub 2023 
      Jun 15.